Wedbush Maintains Neutral on Abivax, Lowers Price Target to $96
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Wedbush analyst David Nierengarten maintains Abivax (NASDAQ:ABVX) with a Neutral and lowers the price target from $118 to $96.
Wedbush analyst David Nierengarten maintains Abivax (NASDAQ:ABVX) with a Neutral and lowers the price target from $118 to $96.